- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.08. | Biotech Stocks At 52-Week Highs - Alamar Biosciences +30% on Q2 Reports, Dyne Therapeutics, Cullinan Therapeutics, DexCom, Cardinal Health | 2.273 | AFX News | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 11, 2026, driven up by key catalysts such as positive quarterly or full year reports.Alamar Biosciences Inc.... ► Artikel lesen | |
| 11.08. | Alamar Biosciences Stock Soars, CEO Says Company Is Well-Positioned to Sustain Upcoming Momentum | 2 | Benzinga.com | ||
| ALAMAR BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 11.08. | Stifel raises Alamar Biosciences stock price target on earnings beat | 1 | Investing.com | ||
| 11.08. | Alamar outlines $116M-$120M 2026 revenue outlook while targeting 100+ instruments and $400,000+ pull-through | 1 | Seeking Alpha | ||
| 10.08. | Alamar Q2 2026 slides: consumables surge 147%, margin hits 60% | 1 | Investing.com | ||
| 10.08. | Alamar Biosciences: Starkes Umsatzwachstum und Rekordmarge bei anhaltenden Verlusten | 4 | Investing.com Deutsch | ||
| 10.08. | Alamar Biosciences expands proteomics partnership by 86,000 samples | 3 | Investing.com | ||
| 10.08. | Alamar Biosciences erweitert Proteomik-Partnerschaft um 86.000 Proben | - | Investing.com Deutsch | ||
| 10.08. | Alamar Biosciences, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 10.08. | Alamar Biosciences, Inc.: Alamar Biosciences Expands Global Partnership with Alzheimer's Disease Data Initiative and Gates Ventures | 3 | GlobeNewswire (USA) | ||
| 28.07. | Alamar Biosciences launches immune profiling panel for research | 1 | Investing.com | ||
| 28.07. | Alamar Biosciences stellt neues Panel zur Immunprofilierung für die Forschung vor | 2 | Investing.com Deutsch | ||
| 28.07. | Alamar Biosciences, Inc.: Alamar Biosciences Launches NULISAseq Immune 340 Panel for Comprehensive Profiling of the Immune Proteome | 422 | GlobeNewswire (Europe) | Expanded panel advances the understanding of immune system across translational and clinical research in cancer, cardiovascular and metabolic diseases, autoimmune diseases and aging
Highly sensitive... ► Artikel lesen | |
| 27.07. | Cathie Woods Biotech-Offensive lenkt den Blick auf datengetriebene Healthcare-Unternehmen - Emyria baut klinische Präsenz aus | Small- & Micro Cap Investment | |||
| 15.07. | Alamar Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.07. | Health Wave Partners Acquires Alamar Senior Living | 1 | pulse2.com | ||
| 14.07. | Alamar Biosciences, Inc.: Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026 | 1 | GlobeNewswire (USA) | ||
| 13.07. | Alamar Biosciences, Inc.: Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases | 478 | GlobeNewswire (Europe) | National-scale initiative will profile ~21,000 plasma samples from 10,000 Alzheimer's Disease and Related Dementias (ADRD) participants using Alamar Biosciences' NULISAseq Neuro 220 panel.
Resulting... ► Artikel lesen | |
| 10.07. | Alamar's platform to feature in 140+ presentations at AAIC | 1 | Investing.com | ||
| 10.07. | Über 140 Präsentationen: Alamar-Plattform im Fokus der internationalen Alzheimer-Konferenz | 1 | Investing.com Deutsch |
1 2 3 Weiter >>
56 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 78,23 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,330 | 0,00 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen | |
| RELAY THERAPEUTICS | 19,760 | 0,00 % | H.C. Wainwright raises Relay Therapeutics price target to $29 | ||
| VERA THERAPEUTICS | 33,680 | -0,12 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| TANGO THERAPEUTICS | 24,510 | 0,00 % | H.C. Wainwright hebt Kursziel für Tango Therapeutics auf 68 US-Dollar an | ||
| ARCUTIS BIOTHERAPEUTICS | 24,780 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 38,150 | 0,00 % | Kaum zu fassen: Die unglaubliche Biotech-Story von Amylyx Pharmaceuticals | Der Biotech-Sektor ist immer wieder für faustdicke Überraschungen gut - sowohl negativ als auch positiv. Bei Amylyx Pharmaceuticals gibt es am Dienstag keine zwei Meinungen: Die Aktie des Biotech-Unternehmens... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 61,15 | 0,00 % | William Blair startet Coverage für Enliven Therapeutics mit "Outperform" | ||
| APOGEE THERAPEUTICS | 134,81 | +0,01 % | AbbVie schließt Anleiheemission über 8,0 Mrd. US-Dollar zur Finanzierung der Übernahme von Apogee Therapeutics ab | ||
| JANUX THERAPEUTICS | 18,600 | 0,00 % | JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know | ||
| PRAXIS PRECISION MEDICINES | 368,25 | +0,06 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,250 | 0,00 % | Recursion, Novavax and Crispr Stocks Trending in Pre-Market-Here's Why | ||
| INHIBRX BIOSCIENCES | 104,94 | 0,00 % | Stifel reiterates Buy on Inhibrx Biosciences stock, $325 target | ||
| SUMMIT THERAPEUTICS | 12,730 | 0,00 % | Summit Therapeutics: Aktie legt nach Hochstufung durch Bernstein zu | ||
| NURIX THERAPEUTICS | 26,270 | 0,00 % | Biotech Stocks At 52-Week Highs - Delcath Systems +22% On Q2 Results, Alto Neuroscience, Hemab Therapeutics, Monopar Therapeutics, Nurix Therapeutics | SOUTH SAN FRANCISCO (dpa-AFX) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming conference participation.... ► Artikel lesen |
ALAMAR BIOSCIENCES INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,03 % bei einem Aktienkurs von 32,690 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALAMAR BIOSCIENCES INC finden Sie auf Wallstreet Online.